Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Target- |
Mechanism Glycolysis inhibitors [+1] |
Active Org. G.ST Antivirals GmbHStartup [+9] |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 May 2021 |
Target- |
Mechanism Glycolysis inhibitors |
Active Org.- |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism DNA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 May 2017 |
Sponsor / Collaborator |
Start Date01 Dec 2015 |
Sponsor / Collaborator Maastro [+2] |
Start Date11 May 2015 |
Sponsor / Collaborator Pfizer Inc. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
14-Aminocamptothecins | Neoplasms More | Preclinical |
Evofosfamide ( DNA ) | Solid tumor More | Suspended |
Lonidamine | Prostatic Hyperplasia More | Discontinued |
Tarloxotinib Bromide ( EGFR x HER2 ) | Non-Small Cell Lung Cancer More | Discontinued |
Flortanidazole F18 | Head and Neck Neoplasms More | Discontinued |